Leuprorelin acetate granulomas: case reports and review of the literature.
Leuprorelin acetate, an agonist of gonadotropin-releasing hormone (GnRH), is indicated in the treatment of prostate cancer. Recently, depot formulations of leuprorelin acetate have been widely used. We report three patients who showed a granulomatous reaction after treatment using a leuprorelin acetate 3-month depot formulation. These patients presented with 5-6-cm subcutaneous nodules at injection sites, which developed after the depot type was changed from a 1-month to a 3-month formulation. Skin biopsy showed epithelioid cells and foreign body giant cells containing round, translucent microspheres which formed sarcoidal granulomas. Changing to other GnRH agonists resulted in no further problems. We have reviewed the previous reports of leuprorelin acetate-induced granuloma formation. The formation of such granulomas may be related to the polymers that allow slow release after injection, or leuprorelin acetate itself may be responsible. The depot injection methods using leuprorelin also seem to have a causal effect in granuloma formation. Dermatologists need to know that depot leuprorelin acetate may cause a granulomatous reaction which produces a subcutaneous nodule that might be misdiagnosed as a malignant tumour.
Yasukawa
K
K
Department of Dermatology, National Hospital Organization Hokkaido Cancer Centre, Sapporo, Hokkaido, Japan.
Sawamura
D
D
Sugawara
H
H
Kato
N
N
D000368:Aged; D000369:Aged, 80 and over; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects*; D003692:Delayed-Action Preparations; D006099:Granuloma / Q000139:chemically induced* / Q000473:pathology; D006801:Humans; D007279:Injections, Subcutaneous; D016729:Leuprolide / Q000009:adverse effects*; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy; D012871:Skin Diseases / Q000139:chemically induced* / Q000473:pathology
D018931:Antineoplastic Agents, Hormonal; D003692:Delayed-Action Preparations; D016729:Leuprolide